MDxHealth (MDXH.BR) Stock Price
MDxHealth Price
Revenue has compounded at 19.5% per year over the past 19 years to 94.73 M USD. MDxHealth's net margin stands at -31.1%, up from -130.4% several years earlier. Analysts set a median price target of 7.20 USD, implying 118.7% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
MDxHealth stock price
MDxHealth business model & stock analysis
Frequently asked questions about MDxHealth
The business model of MDxHealth SA revolves around providing innovative molecular diagnostic solutions to improve the diagnosis and treatment of cancer. The company primarily focuses on developing and commercializing diagnostic tests that aid in the early detection, prognosis, and monitoring of various types of cancers, including prostate, bladder, and lung cancer. MDxHealth offers its diagnostic tests through a global network of clinical laboratories and medical institutions. By offering accurate and actionable diagnostic information, MDxHealth aims to support healthcare professionals in making informed treatment decisions and ultimately improving patient outcomes. MDxHealth's business model underscores its commitment to advancing personalized medicine and precision oncology.
MDxHealth SA is primarily active in the healthcare industry, specializing in molecular diagnostics. As a leading company in precision medicine, MDxHealth SA focuses on developing and commercializing innovative tests that aid physicians in diagnosing and monitoring patients with urological diseases, including prostate cancer. With their advanced molecular diagnostic technologies, MDxHealth SA plays a crucial role in providing accurate and actionable information for personalized treatment decisions, ultimately improving patient outcomes in the healthcare sector.
MDxHealth SA faces competition from various companies in the market. Some of its main competitors include Exact Sciences Corporation, Genomic Health Inc., and Myriad Genetics Inc. These companies also operate in the field of molecular diagnostics and offer similar products and services. However, MDxHealth SA distinguishes itself through its innovative technology, extensive testing portfolio, and strong expertise in the field. Engaging in rigorous research and development, MDxHealth SA continuously strives to maintain its competitive edge in the market.
MDxHealth SA is a biotechnology company based in Belgium. Founded in 2003, MDxHealth focuses on developing and commercializing molecular diagnostic tests for cancer. The company primarily focuses on prostate cancer and offers a range of tests, including ConfirmMDx and SelectMDx, which provide insights into the risk and aggressiveness of the disease. MDxHealth's tests are non-invasive and leverage advanced epigenetic technologies to provide accurate and actionable results. With a strong emphasis on research and development, MDxHealth works towards improving patient care and contributing to early detection and personalized treatment options for cancer patients.
MDxHealth SA, a leading healthcare company, has achieved several significant milestones. One of the notable accomplishments is the FDA approval of their prostate cancer diagnostic test, ConfirmMDx®, which has revolutionized the detection process. Furthermore, the company successfully launched SelectMDx®, a non-invasive urine-based test that aids in identifying patients at high risk of aggressive prostate cancer. MDxHealth SA's collaboration with multiple renowned institutions and experts in the field has contributed to their success in driving innovation and improving patient outcomes. With their consistent commitment to research and development, MDxHealth SA continues to pave the way for groundbreaking advancements in oncology.
MDxHealth SA is primarily present in various countries and regions across the globe. The company has a strong international presence and operates in multiple key markets. Some of the primary countries and regions that MDxHealth SA focuses on include the United States, Europe (including Belgium, Germany, France, and the United Kingdom), as well as other parts of the world. This global presence allows the company to reach a wide customer base and expand its market reach. With its strategic presence in these countries and regions, MDxHealth SA aims to provide its innovative diagnostic solutions and personalized medicine services to a diverse range of patients and healthcare professionals.
MDxHealth SA represents values of innovation, integrity, and excellence. The company is dedicated to transforming the field of molecular diagnostics by developing and commercializing advanced tests that contribute to personalized medicine. With a commitment to improving patient outcomes, MDxHealth SA focuses on precision medicine solutions for cancer diagnosis and treatment. Through their groundbreaking technologies and collaborative approach, the company strives to provide accurate and timely information to healthcare professionals, empowering them to make informed decisions for their patients. MDxHealth SA's corporate philosophy centers around patient-centricity, scientific rigor, and global accessibility, making them a leading player in the world of molecular diagnostics.
Analysts currently set an average price target of 9.41 USD for the MDxHealth stock (median: 7.20 USD), implying +186.0 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the MDxHealth stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect MDxHealth to generate revenue of 113.21 M USD and earnings per share of 0.05 USD.
Converted at the current exchange rate, the MDxHealth share trades at 2.94 EUR (3.29 USD).
The MDxHealth share (MDXH.BR) is listed on 5 stock exchanges, including: London (0O8G.L), Frankfurt (O6C.F), München (O6C.MU).
MDxHealth SA is a Belgian biotechnology company specializing in the development of in vitro diagnostics (IVDs) for personalized medicine. The company aims to improve the diagnosis and therapy of cancer by providing more precise and effective tools. It is based in Herstal, with sales offices in Europe, the USA, and Asia. The company operates in three business areas: diagnostics, pharmaceuticals, and laboratory services. In terms of diagnostics, MDxHealth SA develops and distributes biomarker tests for the diagnosis of prostate, bladder, and kidney cancer. These tests help doctors identify patients with more aggressive forms of cancer and determine the most appropriate treatment. In the pharmaceutical area, the company focuses on the development of therapies for prostate cancer and has partnered with Dutch pharmaceutical company Argenx to advance the development of antibodies for the treatment of prostate cancer. The goal of this collaboration is to develop personalized therapy based on individual patient biomarker profiles. MDxHealth SA's laboratory services division offers diagnostic tests and consulting services to patients and doctors. The company has its own clinical laboratory in the USA where the tests it develops are analyzed and evaluated. MDxHealth SA also provides training and education for medical professionals to ensure a wider use and better interpretation of its tests. Some of the company's key products include the SelectMDx and ConfirmMDx tests. SelectMDx is a non-invasive test for the diagnosis of prostate cancer based on the analysis of urine samples. The test provides doctors with an easy way to distinguish between patients at high and low risk of prostate cancer. ConfirmMDx is another diagnostic test for identifying patients who may require a repeat prostate biopsy. The test allows doctors to detect prostate cancer with greater accuracy and avoid unnecessary biopsies. MDxHealth SA works closely with medical institutions, associations, and authorities to raise awareness of its tests and technologies and promote personalized medicine. The company also maintains close relationships with research institutions and universities to advance its research activities and develop innovative solutions to improve cancer diagnosis and therapy. Overall, MDxHealth SA's business model is focused on providing better diagnostic tests and personalized therapies for cancer patients. The company combines research and development, sales, and consulting services to establish and sell its products and services in the market.
The expected revenue of MDxHealth is 113.21 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of MDxHealth is 2.67 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of MDxHealth is currently 61.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the MDxHealth stock.
The price-to-sales ratio (P/S) of MDxHealth is currently 1.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the MDxHealth stock.
The Eulerpool Quality Score for MDxHealth is 4/10.
The ISIN of MDxHealth is BE0003844611. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of MDxHealth is A0J3N3. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of MDxHealth is MDXH.BR. The ticker symbol is used to trade MDxHealth shares on the stock exchange.
MDxHealth stock
All fundamentals and in-depth analysis of MDxHealth
Our stock analysis for MDxHealth stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MDxHealth. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.